CASRAI Dictionary

Category: Policy & Funding News

Reporting and briefings on external policy, regulatory, and funder developments affecting the research community worldwide.

  • NIH Reinstates South Africa Grant Funding: Inside the Subaward Policy Reversal

    The US National Institutes of Health (NIH) has reinstated South Africa grant funding that had been frozen for months, lifting a hold on payments for scores of existing awards after a policy change nearly collapsed one of its largest overseas HIV and tuberculosis research partnerships. The reversal does not undo the underlying policy — a ban on new foreign subawards — but it restores cash flow to active clinical trials and signals how the NIH intends to manage international collaboration going forward.

    For research administrators, sponsored-programs offices, and institutional leaders outside the United States, the episode is a case study in how quickly a funder’s compliance architecture can change, and how little advance notice foreign partners typically get.

    What happened: the subaward ban and its fallout

    On 1 May 2025, the NIH announced it would no longer permit foreign “subawards” — the standard mechanism by which a US-based principal investigator holding a “prime” NIH grant channels a portion of the funds to a collaborating institution abroad. Going forward, foreign partners would instead need to apply for direct awards from the NIH itself.

    The agency framed the change as an effort to improve financial tracking and safeguard national security. In practice, the shift landed on a system that was not ready for it: the NIH’s own staff guidance warned that the infrastructure for processing direct foreign awards might not be operational until 30 September 2025.

    South Africa was disproportionately exposed. The country hosts one of the NIH’s largest overseas research footprints, particularly in HIV and TB clinical trials run through institutions such as the University of the Witwatersrand and the South African Medical Research Council (SAMRC). Disruption had begun even earlier: in March 2025, the NIH moved to freeze or terminate roughly 280 grants tied to South African projects, well before the formal subaward ban took effect.

    The scale of the exposure was significant. In the prior funding year, the NIH had supported approximately 3,600 subawards in foreign countries worth more than $400 million in total. South African institutions alone had been receiving an estimated $100–150 million a year in direct and sub-awarded NIH funding, according to analysis published by Physicians for Human Rights.

    Timeline: from termination to reinstatement

    The sequence of events matters for any institution assessing exposure to future funder policy shifts. The table below sets out the key dates drawn from contemporaneous reporting.

    Date Development
    March 2025 NIH moves to freeze or terminate roughly 280 grants for South African projects
    1 May 2025 NIH formally bans new foreign subawards; requires direct-award applications instead
    27 June 2025 NIH grants official Michelle Bulls confirms existing clinical-research subawards can continue via a new “supplement” mechanism; roughly 100 prime awards to South African researchers permitted to proceed
    30 June 2025 Staff guidance carves out an exception for human-subjects research submitted before the ban
    July 2025 NIH lifts the payment hold on scores of existing South Africa grants, without public explanation
    30 September 2025 (target) NIH’s new direct-award tracking system for foreign partners due to be operational

    Notably, the reinstatement applied to grants that had been frozen, not to the larger population of grants that had been fully terminated. Separately, the NIH has also been under court order to reinstate a portion of the more than 2,000 grants it cancelled nationwide over politically sensitive research topics — a distinct, US-domestic dispute that runs in parallel to the foreign-subaward story.

    Key questions answered

    Have NIH grants been reinstated?

    Yes, partially. In July 2025 the NIH lifted a payment hold on scores of existing South Africa grants and introduced a “supplement” mechanism letting foreign clinical-research subawards continue. It remains unclear whether grants that were fully terminated, rather than merely frozen, will also be restored.

    How many NIH grants have been canceled?

    Across all research areas, the federal government terminated approximately 2,100 NIH grants worth around $9.5 billion, according to tracking by Harvard T.H. Chan School of Public Health. Within that total, roughly 280 South Africa-linked grants were separately frozen or ended starting in March 2025.

    Do South African universities face a funding crisis from the freeze?

    Yes. Institutions including the University of Cape Town and Wits University reported severe financial strain, staff layoffs, and applications for emergency government funding — with the Wits Health Consortium reportedly seeking over R1.8 billion from South Africa’s Treasury to offset the shortfall.

    What it means for foreign subawardees and research offices

    The reversal is narrow, temporary, and administratively burdensome — not a return to the pre-2025 status quo. Institutions that rely on NIH funding through US-based collaborators should treat the following as durable changes rather than transient disruption:

    • Subawards are being phased out for new and renewal applications. The direct-award model is now the NIH’s default path for foreign partners, and institutions should build direct-application capacity rather than assuming subaward continuity.
    • The supplement mechanism is a stopgap, not a policy. An NIH grants official described the conversion process as “a huge administrative lift” — sponsored-programs offices should expect delays and duplicated paperwork during the transition period.
    • Frozen and terminated are legally distinct categories. Institutions holding terminated (not just frozen) awards should not assume the July reinstatement applies to them without written confirmation from their program officer.
    • Compliance offices need contingency plans. Bodies such as NCURA, EARMA, and ARMA have flagged funder-driven subaward volatility as a growing risk category for institutional research administration — not unique to the NIH or to South Africa.

    For research administration teams managing sponsored programmes with US federal funders, the practical lesson is procedural: subaward agreements should now include explicit clauses addressing funder-initiated conversion to direct awards, and institutions should maintain the internal capacity to submit direct NIH applications on short notice.

    What to track going forward

    Three open questions will determine whether this remains a contained South Africa story or a template applied more broadly to NIH’s international grant portfolio.

    First, whether the 30 September 2025 target for a functioning direct-award tracking system holds, or whether the interim supplement mechanism becomes a permanent parallel process. Second, whether the reinstatement logic extends to grants that were fully terminated rather than frozen — a distinction the NIH has not yet resolved publicly. Third, whether other major NIH partner countries in HIV, TB, and global-health research face the same subaward-to-direct-award transition South Africa has already been through.

    For institutions with NIH-funded international partnerships, the prudent posture is to document funder communications carefully, confirm award status (frozen versus terminated) in writing, and monitor NIH policy notices for extensions or modifications to the direct-award transition timeline.

  • NIH Indirect Cost Cap Lawsuit Ends: Final Ruling Explained

    The NIH indirect cost cap lawsuit is over. In early April 2026, the deadline for the Trump administration to petition the US Supreme Court over its blocked attempt to cap National Institutes of Health facilities-and-administrative (F&A) reimbursements at 15% passed without a filing, closing out fourteen months of litigation that began with a February 2025 policy notice and ended with a unanimous First Circuit Court of Appeals ruling in January 2026. For research administrators who have spent a year budgeting around uncertainty, the case is now legally settled — though, as this article explains, the underlying policy debate is not.

    Timeline: From 15% Cap Proposal to Final Ruling

    The dispute began on 7 February 2025, when NIH issued guidance capping reimbursement of indirect costs — overheads such as facility maintenance, laboratory utilities, and administrative support — at 15% for all new and existing grants, replacing rates individually negotiated with each institution that typically ranged from 30% to 70%. Twenty-two state attorneys general, along with universities and organisations including the Association of American Medical Colleges (AAMC), challenged the notice within days.

    Date Development
    7 February 2025 NIH issues Supplemental Guidance capping indirect cost reimbursement at 15%
    10 February 2025 State attorneys general and higher-education associations file suit
    7 April 2025 US District Court issues a permanent injunction blocking the cap nationwide
    6 January 2026 First Circuit Court of Appeals unanimously upholds the injunction
    Early April 2026 90-day Supreme Court appeal deadline lapses; administration formally drops the case

    NIH’s own public estimate, cited in the appeals court’s opinion, put the fiscal effect of the 15% rate at roughly $4 billion in annual reimbursement withheld from institutions; the AAMC separately estimated the cap would have disrupted $6.5 billion in previously committed research funding had it taken effect immediately.

    Why the Appeals Court Ruled the Cap Unlawful

    The First Circuit’s 6 January 2026 decision rested on two grounds. First, the panel found that a flat cap conflicts with Department of Health and Human Services regulations requiring indirect cost rates to be individually negotiated with each institution rather than imposed uniformly. Second, and more decisively, the court pointed to an appropriations rider that Congress has re-enacted every year since 2017 explicitly preventing NIH from altering how it reimburses indirect costs outside the negotiated-rate process.

    Jurisdiction was itself contested. The administration argued that funding disputes belonged before the Court of Federal Claims rather than a district court, drawing on a Supreme Court precedent from a separate case over NIH grant terminations. Writing for the panel, Judge Kermit V. Lipez distinguished that precedent using Justice Amy Coney Barrett’s concurrence in the earlier grant-termination case, which separated challenges to agency-wide policy (properly heard in district court) from disputes over the withholding of already-awarded contract funds. The proposed rate cap, the court reasoned, was exactly this kind of general policy — so the original district court injunction stood.

    With the ruling upheld and no Supreme Court petition filed inside the 90-day statutory window, the injunction is now final and nationwide. The administration also quietly withdrew parallel appeals over comparable rate-cap policies at the Department of Energy, the National Science Foundation, and the Department of Defense, effectively closing the entire family of indirect-cost-cap litigation at once.

    Answer-First Q&A

    What did the NIH’s proposed 15% indirect cost cap actually change?

    The NIH’s February 2025 policy would have replaced individually negotiated facilities-and-administrative rates, which typically ran between 30% and 70%, with a flat 15% cap on all new and existing grants. Institutions, state attorneys general, and higher-education associations argued this ignored real infrastructure costs and breached appropriations law protecting negotiated rates.

    Why did the appeals court say the cap was unlawful?

    The First Circuit Court of Appeals found the cap violated a Department of Health and Human Services regulation requiring individually negotiated indirect cost rates, plus an appropriations rider Congress has re-enacted since 2017 that bars NIH from unilaterally changing how indirect costs are reimbursed without new legislative authority.

    Is the NIH indirect cost cap litigation completely over?

    Yes. The Trump administration’s 90-day window to petition the Supreme Court after the January 2026 First Circuit ruling expired in early April 2026 without a filing. That deadline lapse permanently ends the case, leaving the nationwide permanent injunction against the 15% cap in place.

    Does the ruling mean indirect cost policy will never change again?

    No. The courts blocked only this specific capping mechanism, not future reform. A 2025 executive order still directs federal agencies to favour lower-overhead institutions in funding decisions, and groups such as AAMC continue advancing the FAIR model as a negotiated alternative to a flat cap.

    What the Ruling Means for Institutions

    For research administrators, the practical effect is restoration of the status quo ante: negotiated F&A rates on NIH awards remain enforceable exactly as they were before February 2025. There is no retroactive cap to reconcile, and no need to budget contingency reserves against a 15% ceiling that never took legal effect. That said, the ruling changes the litigation posture, not the political one — a distinction that matters for planning:

    • Negotiated rate agreements stand. Institutions’ existing Facilities and Administrative (F&A) rate agreements with their cognizant federal agency remain the operative basis for NIH indirect cost reimbursement.
    • Subaward flow-through is unaffected. The cap would have applied to NIH indirect costs on subawards as well as prime awards; with the injunction final, subrecipient reimbursement continues on negotiated terms.
    • Executive-order pressure persists. A separate August 2025 executive order instructing agencies to weight funding decisions toward lower-overhead institutions was not addressed by this litigation and remains in force as a policy lever.
    • Watch agency-specific rulemaking. Because the appeals court’s reasoning turned on the specific appropriations rider protecting NIH, institutions should not assume identical legal protection automatically extends to every other federal funder without agency-specific statutory analysis.
    • Transparency debate continues. AAMC’s Heather Pierce has been explicit that the litigation’s end does not resolve underlying questions about how explainable indirect cost rates are to Congress and taxpayers — a conversation research offices should expect to continue independent of any court order.

    What Comes Next for Indirect Cost Policy

    The NIH indirect cost cap lawsuit’s conclusion removes a year of acute legal uncertainty from institutional budgeting, but it does not close the broader policy conversation about how NIH direct and indirect costs are structured, negotiated, or explained. Two threads are worth tracking. First, the AAMC-backed Financial Accountability in Research (FAIR) model proposes a more granular, activity-based way of tracking indirect cost expenses — an alternative to both the old negotiated-rate system and the abandoned flat cap, and one that could shape future NIH grant funding policy change through negotiation rather than unilateral notice. Second, the administration’s remaining lever — the executive order favouring lower-overhead applicants in funding decisions — operates through discretionary award selection rather than rate-setting, so it sits outside what this ruling addressed and could still influence which institutions receive awards even as reimbursement rates themselves stay protected.

    For institutions tracking research administration standards and terminology more broadly, CASRAI’s research administration resources and open glossary of research-administration terms provide grounding definitions that sit alongside funder policy developments like this one.

  • ORI Research Misconduct Policy: 2026 Annual Assurance Renewal Explained

    The ORI research misconduct policy that governs Public Health Service (PHS)-funded research changed materially for 2026, and the annual paperwork cycle that keeps an institution’s assurance active has not paused to accommodate the transition. Every institution that holds a PHS assurance under 42 CFR Part 93 — whether or not it has an open case — must file its Annual Report on Possible Research Misconduct between 1 January and 30 April 2026, and for the first time that filing sits alongside a revised regulatory framework institutions are expected to have already adopted.

    This is a mechanics piece, not a restatement of the Final Rule’s substance. It sets out exactly what the U.S. Department of Health and Human Services’ Office of Research Integrity (ORI) expects institutions to submit for the 2026 assurance renewal cycle, which form to use, and where the transition from the 2005 regulation creates procedural traps for research integrity officers (RIOs) and sponsored-programs staff.

    What changed: the Final Rule and the 2026 effective date

    ORI’s revised Public Health Service Policies on Research Misconduct — published in the Federal Register on 17 September 2024 and codified at 42 CFR Part 93 — took effect on 1 January 2026. It is the first substantive rewrite of the misconduct regulation since 2005, and it introduces more than twenty-five newly defined terms, including “institutional record,” “administrative record,” “intentionally,” and “recklessly,” aimed at tightening consistency across institutional proceedings.

    The core three-part definition of research misconduct is unchanged: fabrication, falsification, or plagiarism (FFP) that represents a significant departure from accepted practices of the relevant research community, committed intentionally, knowingly, or recklessly, and proven by a preponderance of the evidence. What has changed is procedural detail — respondent comment rights on draft investigation reports, record-retention protocols, and interim-action notification triggers are now spelled out in greater depth.

    Critically, the Final Rule is not retroactive. Allegations received before 1 January 2026 continue to be handled under the 2005 version of Part 93 unless the institution and the respondent agree in writing to proceed under the new rule. Institutions running dual-track proceedings across the transition need to document, case by case, which regulatory version applies.

    Who must file an assurance renewal, and via which form

    Any institution that receives PHS-supported research funds — including awards from NIH, CDC, FDA, HRSA, and other PHS agencies — must maintain an active research misconduct assurance with ORI. Once an assurance is established, the institution is obligated to file annually, regardless of whether it received any misconduct allegations that year.

    • Form: Annual Report on Possible Research Misconduct, Form PHS-6349, submitted through ORI’s online Annual Report system (ARPRM).
    • Filing window: 1 January through 30 April each calendar year, covering the prior calendar year’s activity.
    • 2026 deadline: 30 April 2026, covering the reporting period 1 January–31 December 2025.
    • No-activity institutions: institutions with no PHS-supported research or no allegations in the reporting period may still owe a report; small or inactive institutions should confirm with ORI’s Assurance Program whether a Small Institution or no-activity statement applies to their circumstances.
    • Access: ORI’s Annual Report system now requires two-factor authentication (2FA) — institutions should confirm their registered email with the Assurance Program ([email protected]) well before the deadline to avoid last-minute access issues.

    The 2026 assurance renewal checklist

    Beyond the Form PHS-6349 filing itself, 2026 is unusual because institutions are also expected to have brought their internal policies and procedures into alignment with the new 42 CFR Part 93 requirements. ORI published a Sample Policies and Procedures document in June 2025 specifically to help research integrity officers, compliance staff, and institutional counsel update their templates ahead of the 1 January 2026 effective date.

    Item 2005 rule (pre-2026 cases) 2026 Final Rule
    Effective date 16 June 2005 1 January 2026
    Defined terms in 42 CFR Part 93 Baseline set 25+ additional defined terms
    Applies to allegations received Before 1 Jan 2026 (default) From 1 Jan 2026 onward, or earlier by written agreement
    Annual Report on Possible Research Misconduct Form PHS-6349, Jan–Apr window Unchanged: Form PHS-6349, Jan–Apr window
    Institutional policy alignment N/A Sample Policies and Procedures released June 2025

    Institutions preparing their 2026 renewal should treat the filing as a two-part exercise: (1) submit Form PHS-6349 through ARPRM by 30 April 2026 for the 2025 reporting year, and (2) confirm that the policies and procedures referenced in that assurance actually reflect the post-1-January-2026 regulatory text, not the 2005 language many institutional websites still carry. ORI’s own research administration compliance guidance and case-summary archive remain useful references for RIOs benchmarking their inquiry and investigation timelines against the 60-day inquiry and 120-day investigation targets that persist in the revised rule.

    Frequently asked questions

    What is the deadline for the ORI 2026 annual assurance renewal?

    Institutions holding a PHS research misconduct assurance must file the Annual Report on Possible Research Misconduct (Form PHS-6349) between 1 January and 30 April 2026, covering research misconduct activity from the 2025 calendar year, via ORI’s online ARPRM system.

    Which institutions must maintain an ORI research misconduct assurance?

    Any institution receiving Public Health Service-supported research funds — from NIH, CDC, FDA, or other PHS agencies — must hold an active assurance under 42 CFR Part 93 and file annually, even in years with no reported allegations.

    Does the new ORI Final Rule apply retroactively to open cases?

    No. Allegations received before 1 January 2026 are handled under the 2005 version of 42 CFR Part 93 by default, unless the institution and respondent agree in writing to proceed under the revised rule instead.

    What form and system do institutions use to submit their annual report?

    Institutions submit Form PHS-6349 through ORI’s Annual Report on Possible Research Misconduct system (ARPRM), which now requires two-factor authentication tied to the institution’s registered email address.

    Implications for research administrators

    The overlap between the Final Rule’s 1 January 2026 effective date and the routine 30 April annual report deadline compresses an already tight compliance calendar. Research integrity officers now need to reconcile three separate obligations in the same window: filing the standard annual report, confirming that institutional policies match the revised regulatory text, and correctly classifying any pending allegation as either a 2005-rule case or a 2026-rule case for procedural purposes.

    ORI’s most recent published Annual Report, covering 2024 activity, recorded 713 allegations of possible research misconduct and 117 new cases opened that year, with 38 cases carried over from prior years — a caseload that gives some sense of scale for institutions weighing how much internal capacity to dedicate to inquiry and investigation infrastructure under the tightened procedural clock.

    • Audit institutional policy language against ORI’s June 2025 Sample Policies and Procedures document before certifying compliance in the 2026 assurance filing.
    • Tag open cases by intake date to determine which regulatory version (2005 or 2026) governs each proceeding.
    • Confirm ARPRM account access and two-factor authentication setup well ahead of the 30 April deadline — do not wait for filing week.
    • Brief institutional review boards and legal counsel on the expanded defined terms, particularly “recklessly” and “intentionally,” which affect how misconduct findings are documented.

    Looking ahead

    The 2026 cycle is likely to be the messiest transition year institutions face under 42 CFR Part 93 for some time: two regulatory regimes running in parallel, a compressed policy-update timeline, and an unchanged annual filing deadline that does not care which rule applies to a given case. Institutions that treat the 30 April 2026 Form PHS-6349 submission purely as a data return — rather than as an opportunity to verify their underlying policies actually match the current regulation — risk finding gaps only when ORI reviews a proceeding. Research administrators tracking related standards work, including contributor-role and authorship frameworks referenced in misconduct findings, can cross-reference CASRAI’s CRediT contributor role and authorship resources when documenting responsibility in a research record.

  • Research Misconduct Penalties: Vietnam’s New Tiered System

    Vietnam has become the latest country to formalise research misconduct penalties into a graduated, rules-based system. A 25 May 2026 directive from the Ministry of Science and Technology, first reported by Retraction Watch, moves the country from voluntary integrity principles toward enforceable sanctions — written warnings, public apologies, funding claw-backs and indefinite bans — scaled to the severity of the offence. For institutions and funders elsewhere weighing graduated sanctions frameworks, Vietnam’s approach is a live case study in proportionate enforcement.

    Vietnam’s new framework: what the Ministry announced

    The guidance requires every science and technology organisation in Vietnam to adopt formal rules against research misconduct and to follow a defined process for investigating and sanctioning violations. Before the directive, integrity expectations existed mainly as general principles encouraged on a voluntary basis, without a consistent enforcement mechanism across institutions.

    The framework names four categories as the most serious violations:

    • Fabricating data
    • Plagiarising others’ work
    • Concealing conflicts of interest
    • Acts that distort the true nature of the research

    Notably, the guidance also addresses generative-AI misuse directly — creating fake data or images, or citing unverified AI-generated material as a reference are both classed as violations. Researchers are additionally required to run plagiarism checks before submission, retain raw data and research logs, and disclose funding sources, conflicts of interest and any AI use. Confirmed violations must be logged on Vietnam’s National Digital Platform for Science, Technology and Innovation Management, giving the sanctions a permanent, searchable public record.

    A tiered system: how the penalties scale with severity

    Rather than a single blanket punishment, the framework sets out a ladder of responses, so that a first, low-level infraction is treated differently from deliberate fabrication. This proportionality principle is common to most mature integrity systems, but Vietnam’s version is unusually explicit about which penalty attaches to which tier.

    Severity tier Example conduct Typical sanction
    Lower tier Procedural lapses, inadequate disclosure Written warning, mandatory training
    Mid tier Undisclosed conflicts of interest, authorship disputes Correction/retraction request, public apology, role suspension
    Upper tier Fabrication, falsification, plagiarism, concealed AI misuse Return of research funding, permanent or indefinite project ban

    The Ministry’s move follows years of pressure from documented cases. Retraction Watch’s database records 251 retractions carrying a Vietnamese institutional affiliation, with Ton Duc Thang University and Duy Tan University accounting for the largest share. Investigative reporting by the newspaper Thanh Nien in 2020 found foreign academics were being paid to falsely list affiliations with Vietnamese universities to inflate publication counts and rankings — at one point roughly 70% of Ton Duc Thang’s 2022 publications involved external, unaffiliated researchers. A separate 2022 investigation into a large Russian paper mill placed Vietnamese researchers among its top ten purchasers of fabricated authorship slots.

    Tu Van Duong, a senior researcher at Purdue University, described the directive as an “important milestone,” noting that Vietnam’s integrity expectations had previously relied on general principles and voluntary encouragement rather than binding enforcement.

    Common questions on research misconduct penalties

    What are the penalties for research misconduct?

    Penalties typically form a graduated scale: written warnings and retraining for minor lapses, followed by correction or retraction of publications, mandatory supervision, and — for the most serious cases — loss of employment, revoked degrees, permanent funding bans, and in rare cases criminal prosecution for misuse of public funds.

    What are the three types of research misconduct?

    Most frameworks, including the US federal definition and Vietnam’s new guidance, converge on three core categories: fabrication (inventing data or results), falsification (manipulating data, equipment, or processes to misrepresent findings), and plagiarism (using others’ ideas or words without credit).

    What happens if you get caught for academic misconduct?

    An institutional panel investigates the allegation, typically involving academic peers and external members. If misconduct is confirmed, consequences range from a formal reprimand or required correction through to suspension, termination, degree revocation, and referral to funders or professional bodies for further sanction.

    Who investigates allegations of research misconduct?

    Primary responsibility usually sits with the researcher’s own institution, guided by a code of practice such as the UK’s Concordat to Support Research Integrity. National bodies — Vietnam’s Ministry of Science and Technology, the US Office of Research Integrity, Germany’s DFG — provide oversight, funding sanctions, or an appellate role rather than running every case.

    How Vietnam compares: graduated sanctions worldwide

    Vietnam is not acting in isolation. Several jurisdictions have tightened or formalised research misconduct policy in the same window, reflecting a broader shift toward proportionate, publicly verifiable enforcement.

    Jurisdiction / body Mechanism Notable feature
    United States (ORI, NSF) Debarment from federal funding Confirmed cases published publicly
    United Kingdom (UKRI) Funding withdrawal, application bar Institutions face sanction if investigations are inadequate
    Germany (DFG) Exclusion from applying for funds 1–8 year bans, published sanctions list
    Canada (Tri-Agency) Reprimand to lifetime funding ban Comparatively low public transparency
    Scotland (May 2026) New institutional integrity system requirements Sector-wide baseline standard
    Peru (March 2026) Faculty bonus eligibility rules Bars bonuses for researchers with retractions
    India Grant-application disclosure requirement Five-year retraction history must be declared
    Thailand (THRIN) National research integrity network Cross-institutional coordination body
    Vietnam (May 2026) Tiered warnings to indefinite bans Violations logged on a national digital platform

    The common thread is a move away from vague, principle-only guidance toward codified, tiered sanctions with a public or semi-public record — precisely the design pattern uk research misconduct bodies such as UKRIO have long recommended through the Concordat to Support Research Integrity, and that international bodies including the European Network of Research Integrity Offices (ENRIO) are working to harmonise across borders.

    Implications for institutions and research administrators

    For research administrators, Vietnam’s framework is a useful reference point when reviewing a local research misconduct policy. Three implications stand out:

    • Proportionality reduces case backlog. A defined tier structure lets institutions resolve low-severity cases with training or a warning, reserving lengthy formal investigations for fabrication, falsification and plagiarism.
    • Public logging changes deterrence dynamics. A searchable national record — as opposed to institution-only files — raises the reputational stakes of a confirmed finding, mirroring the public debarment lists already run by the US Office of Research Integrity and Germany’s DFG.
    • AI-specific clauses are becoming standard. Explicitly naming fabricated AI outputs and unverified AI citations as misconduct closes a gap that many older policies, including some still in force across UK and EU institutions, have not yet updated to cover.

    Misattributed or inflated authorship — the practice exposed at Ton Duc Thang and Duy Tan — is itself a form of research misconduct, and one that transparent contributorship reporting can help deter. CASRAI originated the CRediT contributor role taxonomy in 2014 to make individual research contributions auditable; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. Institutions building or revising misconduct policy alongside authorship criteria and contributor role disclosure requirements give investigators a clearer evidentiary trail when authorship claims are disputed. For teams mapping their own procedures against comparable frameworks, CASRAI’s research administration resources and research integrity terminology reference are a starting point.

    What comes next

    Vietnam’s National Digital Platform will take time to populate, and enforcement consistency across thousands of institutions and provincial science agencies remains untested. The real signal will be whether confirmed cases are actually logged, sanctioned and made visible — the same accountability gap that has historically limited Canada’s Tri-Agency framework and left some European systems reliant on anonymised summaries rather than named findings.

    What is clear is the direction of travel. Alongside Scotland’s new institutional requirements, Peru’s bonus restrictions, and India’s disclosure rules, Vietnam’s tiered penalties add to a growing body of 2026 evidence that funders and governments are converging on graduated, publicly verifiable sanctions rather than one-size-fits-all punishment. For institutions still relying on ad hoc disciplinary procedures, that convergence is now the benchmark to measure against.

  • Scotland’s New Research Integrity Policy: What UK Institutions Must Do Before September 2026

    The Scottish Funding Council (SFC) approved a new research integrity policy in May 2026, and it takes effect on 1 September 2026 for every Scottish higher education institution that receives SFC research and innovation funding. The policy is not a rewrite of institutional codes of conduct — those remain the responsibility of individual universities — but it introduces a mandatory reporting relationship between institutions and their funder that did not previously exist in Scotland, and it gives research offices a firm compliance deadline to work against.

    For pre-award, governance and research integrity teams, the practical question is not whether the policy is welcome — it broadly restates principles already embedded in the UK-wide Concordat to Support Research Integrity — but what operational changes are needed before the start date, and how Scotland’s approach compares with the mechanisms already in place across the rest of the UK.

    What the Scottish Funding Council’s new policy requires

    The SFC policy defines research integrity in terms consistent with UK Research and Innovation’s (UKRI) own framing: research that is trustworthy, ethical and responsible, guided by five principles — honesty, rigour, transparency and open communication, care and respect, and accountability. Those five principles mirror the commitments set out in the revised Concordat to Support Research Integrity, so institutions already aligned with the Concordat are not starting from zero.

    The operative change is procedural. Under the new policy, institutions receiving SFC research and innovation funding must notify the Council of the outcome of any formal investigation into research misconduct, with a benchmark turnaround of no more than one month following the investigation’s conclusion. This is a step beyond the general expectation, long established through the Concordat, that funded organisations simply maintain “appropriate structures, policies and procedures” to support integrity — it creates a specific, time-bound reporting obligation tied to SFC funding.

    Three scope points matter for compliance planning:

    • The policy applies to Scottish higher education institutions that receive SFC research and innovation funding, and to research activity the Council funds directly.
    • The SFC will not act as an appeals body for individual misconduct cases, will not support individuals through investigations, and will not grant ethical clearance for research projects — those functions stay with the institution and, where applicable, research ethics committees.
    • The Council reserves the right to act where misconduct is reported, which may include action relating to individuals or a review of an institution’s own processes and systems — a lever that raises the stakes of a weak or slow internal investigation process.

    How it fits the UK-wide Concordat to Support Research Integrity

    The Scottish policy is explicitly framed as complementary to, not a replacement for, the Concordat to Support Research Integrity — the UK-wide framework signed by universities, funders and sector bodies and refreshed in April 2025. The revised Concordat broadened its recognition of contributors to research beyond principal investigators to include research-enabling staff such as technicians, data managers and research development professionals, and it updated its language on questionable research practices.

    The UK Research Integrity Office (UKRIO) updated its own UKRIO Code of Practice for Research to Version 3.5 in July 2025 specifically to align with the revised Concordat, adding new guidance on the responsible use of AI and other emerging technologies in research, and deliberately softening language around misconduct procedures to reduce the stigma that UKRIO’s own 2024 research found was discouraging staff from reporting concerns. Scotland’s new policy sits on top of this existing architecture: it does not change what “good research conduct” means, but it changes who has to be told when conduct falls short, and how quickly.

    Scotland versus the rest of the UK: a comparison

    No other UK funding council currently mandates misconduct-outcome reporting on the same timetable as the SFC. The table below sets out how the main frameworks compare for a Scottish, UK-wide and cross-border institution.

    Framework Scope Misconduct reporting to funder Status from September 2026
    SFC Research Integrity Policy Scottish HEIs receiving SFC research/innovation funding Mandatory outcome notification, benchmark of one month post-conclusion Mandatory, funding-linked
    Concordat to Support Research Integrity (2025) UK-wide, all signatory institutions and funders General expectation of appropriate structures and annual statements; no fixed reporting clock Voluntary sector commitment
    UKRI Guidance on Investigation of Research Misconduct Organisations holding UKRI grants, UK-wide Requires investigation of allegations against funded staff/students; reporting terms set out in grant conditions Grant-condition based
    UKRIO Code of Practice for Research (v3.5) Any UK or international research organisation, adoptable in full or in part No reporting mandate; benchmark and advisory framework only Voluntary adoption

    The practical effect for cross-border institutions — a Scottish university with UKRI grants, for example, or a UK-wide research group with a Scottish node — is that the SFC clock now runs in parallel with, not instead of, existing UKRI grant conditions and Concordat commitments. Research offices need a single misconduct-tracking process that can satisfy the tightest of the applicable deadlines, rather than separate parallel logs.

    What pre-award and research offices must change before September 2026

    With roughly two months between SFC approval and the effective date, research integrity and governance teams have a narrow window to close gaps. The priority actions are:

    • Map the reporting chain. Confirm who in the institution is authorised to notify the SFC of an investigation outcome, and build the one-month clock into the misconduct investigation procedure itself, not as an afterthought once a case closes.
    • Audit investigation timelines. If current misconduct procedures routinely run beyond a month from conclusion to formal sign-off, the reporting deadline effectively compresses the institution’s own internal process.
    • Update the annual statement on research integrity. Institutions already produce a Concordat-aligned annual statement; this is the natural place to reference the new SFC notification duty and evidence compliance.
    • Brief research ethics committees and REI managers. The SFC has been explicit that it will not adjudicate individual cases or grant ethical approval, so institutions cannot rely on the Council to absorb any of that governance load.
    • Cross-check against UKRI and other funder conditions. Where a case involves UKRI or other funding alongside SFC money, confirm which reporting obligation applies first and ensure both are met.

    Questions institutions are asking

    What is a research integrity policy?

    A research integrity policy is an institutional or funder document setting out the standards of honesty, rigour, transparency, care and accountability expected in research, alongside the roles, training and procedures — including misconduct investigation — that put those standards into practice across the research lifecycle.

    What is the Concordat to Support Research Integrity?

    The Concordat to Support Research Integrity is a UK-wide sector agreement, signed by universities, funders and representative bodies, committing signatories to five shared responsibilities for maintaining rigour, transparency and accountability in research, most recently revised in April 2025.

    Who investigates research misconduct in the UK?

    Individual institutions investigate research misconduct allegations under their own procedures, informed by the UKRIO Code of Practice for Research; funders such as UKRI and, from September 2026, the SFC in Scotland, set reporting conditions but do not conduct the investigations themselves.

    What happens if an institution breaches its research integrity policy?

    Consequences depend on the framework: internally, breaches can trigger disciplinary action up to dismissal; externally, funders including the SFC can review an institution’s processes and systems, and in serious cases reconsider its funding relationship, though the SFC has stated it will not act as an appeals body.

    Implications beyond Scotland

    Scotland’s move is likely to be watched closely by the other UK nations’ funding bodies as a test case for whether time-bound, funder-mandated misconduct reporting improves transparency without overwhelming research offices. For institutions operating research programmes across borders — a common pattern for Russell Group and consortium-led projects — the immediate implication is administrative: misconduct-case tracking systems built around a single national timetable now need to accommodate a jurisdiction-specific clock for any Scottish-funded strand of work.

    There is also a signalling effect for research culture more broadly. Mandatory outcome reporting, even where the funder is explicit that it will not re-adjudicate cases, tends to raise the internal profile of misconduct procedures and can influence how quickly institutions resource investigation teams. Given UKRIO’s own 2024 finding that fear of stigma was a barrier to reporting concerns, institutions would do well to pair procedural compliance with the destigmatising language changes UKRIO built into Version 3.5 of its Code, rather than treating the SFC deadline as a purely administrative exercise.

    What to watch next

    Three things are worth tracking as the September 2026 start date approaches: whether the SFC publishes supporting guidance or a template notification form ahead of the deadline; whether other UK funders signal an intention to introduce comparable time-bound reporting; and how the first wave of notified outcomes, likely to surface in aggregate through SFC or Universities Scotland reporting during 2027, shapes the sector’s view of whether mandatory reporting changes behaviour or simply changes paperwork. Research offices that treat the current window as a chance to audit and tighten investigation timelines — rather than a compliance box to tick in August — will be best placed regardless of how the policy evolves.

  • cOAlition S Monographs: What the Open Access Policy Requires

    University presses tracking funder mandates often conflate two distinct policy layers. cOAlition S monographs guidance — the coalition-wide recommendations issued by the group of research funders behind Plan S — is not the same instrument as the Horizon Europe monograph mandate that already binds beneficiaries of European Commission grants. The two are related but legally and operationally distinct, and the gap matters for any press negotiating embargoes, licences, or rights-retention clauses with an academic author.

    This explainer sets out what cOAlition S itself asks of its 20-plus funder members regarding academic books, how that differs from the binding Horizon Europe rules, and where university presses need to track both.

    What cOAlition S Actually Recommends for Monographs

    Plan S, launched in 2018, was built around Principle 7, which acknowledged that “the timeline to achieve Open Access for monographs and book chapters will be longer and requires a separate and due process” than for journal articles. cOAlition S formalised its position on academic books — defined broadly to include monographs, book chapters, edited collections, and critical editions — in a dedicated statement published on 2 September 2021.

    Crucially, that statement is framed as a set of recommendations, not a uniform mandate. Individual cOAlition S organisations are asked to adopt the following within their own remits:

    • Academic books based on funded original research should be made open access on publication.
    • Authors or their institutions should retain sufficient intellectual property rights to enable open access and re-use.
    • Books should be published under a Creative Commons licence.
    • Embargo periods should be as short as possible and must never exceed 12 months.
    • Funders should financially support open access book publishing through dedicated schemes.

    This is a coordination framework, not a single rulebook. Each member funder — UKRI, Wellcome, the Austrian Science Fund (FWF), the Dutch Research Council (NWO), Science Foundation Ireland, and others — then writes its own policy inside those boundaries, which is precisely why embargo lengths and licence choices still vary from funder to funder.

    Timeline: How the Monograph Statement Emerged

    The gap between journal and book policy was deliberate, not an oversight. Plan S’s original 2018 principles applied in full to peer-reviewed journal articles from 1 January 2021, but books were explicitly carved out for a “separate and due process.” cOAlition S’s Implementation Guidance committed the coalition to issuing a books-specific statement “by the end of 2021” — a deadline it met with the September 2021 publication.

    Since then, cOAlition S has continued developing technical guidance for open access books in collaboration with existing infrastructure providers, including the Directory of Open Access Books (DOAB) and the OAPEN open access books toolkit, rather than imposing a single technical standard by decree.

    Licensing and Embargo Rules Compared Across Funders

    Because cOAlition S sets a ceiling rather than a fixed rule, the practical requirements a university press encounters depend entirely on which funder supported the underlying research. The table below compares the coalition-wide recommendation with several member funders’ actual policies, including the European Commission’s Horizon Europe rules.

    Funder / Framework Scope Maximum embargo Licence
    cOAlition S (coalition recommendation) Academic books based on funded original research 12 months Any Creative Commons licence
    Horizon Europe (European Commission) All books, monographs and long-text outputs, if peer-reviewed 0 months (immediate) CC BY, CC BY-ND or CC BY-NC (or equivalent)
    UKRI Monographs, book chapters, edited collections (from 1 Jan 2024) 12 months Any Creative Commons licence
    Wellcome Scholarly monographs and book chapters 6 months CC BY preferred; other CC licences permitted
    FWF (Austria) Peer-reviewed research results of FWF-funded research 12 months (only if FWF has not financially supported the book) CC BY and CC BY-NC required
    Research Council of Norway Academic books, monographs, edited collections, anthology chapters 12 months (immediate recommended) CC BY, CC BY-ND, CC BY-NC or equivalent

    The pattern is consistent: Horizon Europe is the strictest implementation of the cOAlition S framework, not a separate policy philosophy. As an EU funding programme whose managing body sits within cOAlition S, Horizon Europe simply exercises the option every member funder has — to set its own embargo and licence rules inside the coalition’s 12-month ceiling — and chooses the tightest possible setting: zero embargo.

    Where cOAlition S and Horizon Europe Overlap — and Diverge

    The overlap is principled: both frameworks require Creative Commons licensing, both expect rights retention sufficient to enable re-use, and both trace back to the same Plan S lineage. The divergence is procedural and binding. cOAlition S’s book statement is aspirational guidance that individual funders “will seek to adopt,” whereas the Horizon Europe rules sit inside the Model Grant Agreement that every beneficiary signs — making non-compliance a contractual, auditable matter rather than a best-practice lapse.

    What is Plan S?

    Plan S is an open access initiative launched in 2018 by cOAlition S, a group of national and international research funders. It requires immediate open access to peer-reviewed journal articles from funded research, with a separate, later-developed framework for monographs and book chapters.

    Does cOAlition S require open access for monographs?

    cOAlition S recommends rather than mandates open access for monographs. Its September 2021 statement asks member funders to adopt open access on publication, Creative Commons licensing, and a maximum 12-month embargo within their own policies — leaving each funder to set the binding rule.

    How does the Horizon Europe monograph mandate differ from cOAlition S?

    Horizon Europe imposes a binding, zero-embargo open access requirement for peer-reviewed monographs funded under the programme, embedded in its Model Grant Agreement. cOAlition S’s own statement is coalition-wide guidance permitting member funders up to a 12-month embargo, making Horizon Europe the strictest single implementation of that broader framework.

    What licence does cOAlition S recommend for open access books?

    cOAlition S recommends publication under any Creative Commons licence, without mandating a single variant. Horizon Europe narrows this for its own grantees to CC BY, CC BY-ND or CC BY-NC (or a licence with equivalent rights), reflecting the sector’s greater sensitivity around commercial and derivative rights for books than for journal articles.

    Implications for University Presses and Institutions

    For presses and library publishing units, the practical task is to identify the funder, not the coalition, before setting contract terms. A monograph funded partly by Horizon Europe money is bound by the zero-embargo rule regardless of what cOAlition S’s general statement permits; a monograph funded by an FWF grant that did not directly support book production may carry a 12-month embargo instead.

    Several operational consequences follow:

    • Contracts and rights-retention clauses should be drafted per funder, not per generic “Plan S compliance” assumption.
    • Long-term data preservation and hosting arrangements matter as much as the embargo date — cOAlition S technical guidance points presses toward trusted infrastructure such as DOAB and OAPEN, mirroring the repository requirements it already sets for journal articles and datasets.
    • Mixed-funding books (part Horizon Europe, part national funder) should default to the strictest applicable rule to avoid inadvertent non-compliance.
    • Research administration teams should track funder-specific embargo tables rather than relying on a single “Plan S” checklist, since the coalition itself does not enforce one.

    Institutions with dedicated research administration functions are best placed to reconcile these variations before contracts are signed, rather than after a book has gone to press. CASRAI’s broader work on funder compliance and research administration processes is directly relevant to teams building these internal checklists.

    What Comes Next

    cOAlition S has signalled it is moving toward a more flexible, multi-model approach to open access generally, following its own December 2025 strategy review — a shift chronicled by outlets including Chemistry World. For monographs specifically, this makes near-term convergence toward a single binding coalition-wide rule unlikely; the recommendation-based structure suits the genuine diversity of book publishing economics across disciplines and countries far better than a uniform mandate would.

    University presses should therefore expect the current two-tier reality to persist: a coalition-wide floor of open access, Creative Commons licensing and a 12-month embargo cap, with individual funders — Horizon Europe most prominently — free to set stricter terms for their own grantees. Tracking both layers, rather than treating “Plan S” as one monolithic rule, remains the only reliable compliance strategy.

  • cOAlition S Scales Back: Inside the Open Access Commitment Reset

    On 12 November 2025, cOAlition S published a statement titled “cOAlition S reinforces Open Access commitment while advancing next strategic phase.” The framing was affirmative, but the substance was a retreat. The cOAlition S open access commitment for 2026-2030 drops the all-funder compliance mandate that defined Plan S since 2018 in favour of three broader, less prescriptive priorities — and December 2025 trade coverage, including Chemistry World, read the move for what it is: a narrowing of ambition after seven years of uneven enforcement.

    For research administrators who built compliance workflows, journal-checker integrations, and funder-reporting templates around the original all-or-nothing mandate, this is not a footnote. It is a structural change in what “Plan S compliant” means going forward.

    What cOAlition S actually announced in November 2025

    cOAlition S — the international consortium of research funders formed in 2018, coordinated through Science Europe — published its Strategy 2026-2030 alongside the November statement. Mari Sundli Tveit, Chief Executive of the Research Council of Norway and Chair of the cOAlition S Leaders Group, said the coalition remains “determined to accelerate full and immediate Open Access,” while explicitly widening the mission to include transparency, equity, and the trustworthiness of scientific knowledge.

    Three strategic priorities now anchor the plan:

    • Strengthening the foundations for full, immediate, sustainable, and equitable open access to peer-reviewed scholarly articles.
    • Supporting the digital infrastructure that underpins open access publishing.
    • Exploring financially sustainable, equitable publishing systems while monitoring their progress and impact.

    Notably, the statement does not repeat the 2018 promise of a single, enforced compliance deadline for all member funders. Instead it describes “extensive member consultation” and implementation that will “unfold collaboratively over the following months” — language that signals coordination rather than a mandate with teeth.

    Plan S 2018 versus the 2026-2030 strategy: what changed

    Plan S launched in September 2018 with twelve founding funders and a hard requirement: from 2021, all peer-reviewed publications resulting from grants awarded by cOAlition S members had to appear in fully open access journals or platforms, or be deposited immediately in a repository without embargo, under a CC BY licence. It was designed as an all-or-nothing mandate — no partial credit, no member opt-outs on the core requirement.

    The clearest concrete break in the 2026-2030 strategy is the end of coalition-wide financial support for “transformative arrangements” (read-and-publish and similar hybrid-journal deals), which member funders had already agreed to stop funding after 2024. Those agreements were originally sold as a bridge to full open access; cOAlition S’s own strategy materials now treat their expiry as settled, while the harder question — what replaces them at scale — is deferred to the “exploring financially sustainable, equitable publishing systems” priority rather than answered outright.

    Dimension Plan S (2018 launch) cOAlition S Strategy 2026-2030
    Compliance model Single mandatory deadline (2021) for all member-funded outputs Coordinated priorities, member-level implementation timelines
    Core licence requirement CC BY, no embargo Unchanged — still CC BY, no embargo, where applicable
    Transformative agreements Tolerated as a temporary bridge Coalition funding ended after 2024
    Scope of mission Full and immediate open access Adds transparency, equity, trustworthiness, AI-era research integrity
    Governance framing Uniform mandate across members “Diverse national and international contexts,” unified advocacy rather than enforcement

    What has not changed, per cOAlition S’s own materials: the underlying licensing requirement (CC BY, no embargo) still applies where a member funder’s policy invokes it. What has changed is the coalition-level machinery that once stood behind that requirement as a shared, enforced deadline.

    What enforcement looks like now

    The 2018 model relied on a shared Journal Checker Tool, coordinated funder policies, and the implicit threat of a synchronised 2021 deadline across all members. The 2026-2030 model relies instead on individual funder policies operating inside a shared strategic direction — each cOAlition S member (among them UKRI, the Wellcome Trust, and the European Commission via Horizon Europe) continues to set and enforce its own grant conditions, but the coalition itself is stepping back from presenting those conditions as a single synchronised mandate.

    This is a meaningful distinction for anyone doing compliance work:

    • Funder-level open access requirements (UKRI’s policy, Horizon Europe’s Open Research mandate, Wellcome’s policy) remain in force and are not softened by the coalition statement.
    • What is softened is the coalition-wide narrative that all of this adds up to one enforced standard with one compliance bar.
    • Institutions should expect continued policy divergence between funders rather than the convergence Plan S originally promised.

    Common questions about the open access commitment

    What is Plan S in open access?

    Plan S is the 2018 open access mandate from cOAlition S requiring that peer-reviewed publications funded by member grants be made immediately available, without embargo, under a CC BY licence — either via a compliant open access venue or an institutional repository.

    Has cOAlition S dropped its open access mandate?

    No — cOAlition S has not dropped the underlying licensing requirement. What changed is the coalition-level enforcement model: the Strategy 2026-2030 replaces a single all-funder compliance deadline with three broader strategic priorities and funder-level implementation.

    Who are the cOAlition S funders?

    cOAlition S launched in 2018 with twelve national and international research funders and has since grown; current members include research councils and funding bodies coordinated through Science Europe, alongside participants such as the European Commission via Horizon Europe. Membership composition is published on coalition-s.org.

    Are transformative agreements still funded under Plan S?

    No. cOAlition S member funders confirmed the end of financial support for transformative arrangements such as read-and-publish deals after 2024, treating them as an expired transitional measure rather than a permanent open access route.

    Implications for institutional compliance workflows

    Institutions that built compliance infrastructure — journal-checker integrations, repository deposit workflows, funder-reporting dashboards — around the assumption of one synchronised cOAlition S standard now need to re-map that infrastructure to individual funder policies. The practical risk is not that requirements have loosened; UKRI, Wellcome, and Horizon Europe policies are each still active and still require licence and embargo compliance on their own terms. The risk is assuming coalition-level messaging still functions as a single compliance proxy for all of them.

    Research offices should treat the 2026-2030 strategy as a signal to audit funder policies individually rather than defer to a “Plan S compliant” shorthand that no longer maps cleanly onto one enforced standard. That audit work sits alongside related contributor-transparency and authorship-attribution practices that institutions are already tracking — for example through the CRediT contributor role taxonomy, which CASRAI originated in 2014 and which is now stewarded by NISO as ANSI/NISO Z39.104-2022, and through broader research administration compliance frameworks.

    The next twelve months matter. cOAlition S has said implementation of the new strategy will “unfold collaboratively” — which means the concrete compliance detail research offices actually need (updated guidance, any revised Journal Checker Tool logic, member-by-member timelines) is still being written. Institutions that wait for a single unified answer, as they could under the 2018 framing, are likely to be waiting through most of 2026. The more defensible posture is to track each funder’s policy directly and treat the coalition strategy as directional context rather than an enforceable standard in its own right.

  • AI Chip Export Controls: How 2026 Rules Reshape Research Collaboration

    University research offices spent 2025 building compliance playbooks around chip-specific licensing regimes, and 2026 has already rewritten them. AI chip export controls research is no longer a niche trade-law question for a handful of national-security-adjacent labs — it now shapes which GPUs a computer science department can buy, which foreign postdoctoral researchers can touch a controlled cluster, and which international co-authors can be looped into a compute-heavy project. This article isolates the advanced-chip and compute-specific rules from the broader ITAR/EAR fundamental-research-exclusion debate, because the two interact in ways that catch research administrators off guard.

    What changed: the AI chip export control landscape in 2026

    The current regime traces back to the US Commerce Department’s October 2022 controls on advanced semiconductors and chip-making equipment destined for China. The Biden administration’s January 2025 “AI Diffusion Rule” extended this into a three-tier country framework, but the Trump administration rescinded it in May 2025 before it took full effect.

    Policy has moved quickly since. Key 2025-26 milestones for research offices to track:

    • September 2025 — Commerce guidance confirmed any use of Huawei’s Ascend AI chips violates existing export controls, per a Congressional Research Service report (Congress.gov, R48642).
    • December 2025 — the White House announced a policy reversal permitting conditional sales of advanced Nvidia and AMD accelerators to China.
    • 13 January 2026 — Commerce codified this in a new regulation setting revised performance thresholds (chips with a total processing performance below 21,000 or DRAM bandwidth below 6,500 GB/s), a 50% volume cap relative to US shipments, and mandatory end-use “know your customer” certification.
    • January 2026 — a 25% tariff was added to AI chip exports to China, layering trade policy on top of national-security licensing.

    Congress is running a parallel track: the Chip Security Act, still moving through committee, would require exporters to verify the physical location of controlled chips after sale — a location-tracking obligation with direct implications for any university that hosts hardware jointly funded or co-located with an overseas partner institution.

    Hardware controls vs the Fundamental Research Exclusion

    Most institutional export-control training focuses on the Fundamental Research Exclusion (FRE), which removes published, unrestricted university research from “technology” and “technical data” controls under the Export Administration Regulations (EAR) and the International Traffic in Arms Regulations (ITAR). That framing is necessary but insufficient for AI chips.

    The FRE exempts information — research results intended for open publication. It does not exempt the physical item. A controlled GPU cluster remains a controlled export item regardless of whether the resulting paper will be published openly. This distinction matters because:

    • Procuring, importing, or re-exporting a covered accelerator still requires a licence or licence exception, independent of publication intent.
    • The EAR’s “deemed export” rule treats the release of controlled technology to a foreign national inside the US as an export to that person’s home country — so granting a visiting researcher administrator-level access to a controlled cluster can trigger a licensing requirement even when the research itself is unclassified and destined for a journal.
    • Cloud and remote-access provisioning now falls inside scope for some controls, meaning offshore collaborators accessing a US-hosted cluster remotely can raise the same deemed-export question as physical hardware transfer.

    Research administrators who apply only the “will this be published?” test are missing this hardware layer entirely.

    Effects on international co-authorship and lab procurement

    Two operational pressures are converging on university AI labs. First, procurement: institutions outside the US increasingly cannot source the newest-generation accelerators at all, or face multi-month allocation queues even where licensing exists, forcing reliance on lower-tier chips or shared national compute facilities. Second, collaboration: compliance offices are becoming more cautious about admitting foreign graduate students and visiting scholars onto projects that touch controlled hardware, out of concern for inadvertent deemed-export violations — a dynamic some analysts describe as pushing labs toward “partitioned research spaces” accessible only to a security-cleared subset of a research group.

    The regulatory detail differs meaningfully by jurisdiction, which matters for any multi-country consortium:

    Jurisdiction Controlling authority Core mechanism Relevance to university labs
    United States Bureau of Industry and Security (Commerce) Item-specific chip thresholds, deemed-export rule, end-use certification Direct licensing burden on procurement and on foreign-national lab access
    United Kingdom Export Control Joint Unit (Department for Business and Trade) UK Strategic Export Control Lists, aligned to the Wassenaar Arrangement dual-use list Universities UK / NPSA “Trusted Research” guidance shapes due diligence on overseas partnerships
    European Union EU Dual-Use Regulation + AI Act Dual-use export licensing plus AI Act compute thresholds for general-purpose models AI Act Article 51 sets a 10^25 FLOPs systemic-risk trigger, indirectly linking model compute scale to regulatory scrutiny
    Wassenaar Arrangement 42-member multilateral forum Voluntary dual-use control list Has not reached consensus on binding AI-chip-specific controls, leaving the US to act largely unilaterally

    The absence of Wassenaar consensus on AI-chip-specific controls is a genuinely underreported detail: it means the US regime is not a multilaterally harmonised standard but a unilateral extension that allied nations’ universities must interpret alongside their own domestic dual-use rules — a compliance gap that a single-jurisdiction FRE briefing will not surface.

    Common questions on AI chip export controls and research

    What is the US export control on AI chips?

    The US controls advanced AI accelerators and related manufacturing equipment under the Export Administration Regulations. The January 2026 rule sets performance thresholds, a 50% volume cap on chips sold to China relative to US shipments, and mandatory end-use certification — replacing the rescinded 2025 AI Diffusion Rule’s country-tier system.

    Are Nvidia chips export controlled?

    Yes. Nvidia’s most advanced accelerators require licensing for restricted destinations. The 2026 regulation specifically loosened restrictions on Nvidia H200 and AMD MI325X chips for conditional sale to China, subject to volume caps, security certification, and a 25% tariff — a partial reversal of the prior blanket restriction.

    Who supplies China with AI chips?

    Nvidia and AMD remain the dominant US suppliers under licensed, conditional export terms, while Chinese firms such as Huawei supply domestic alternatives like the Ascend series. Analysts estimate licensed exports could raise China’s installed AI compute substantially in 2026, even under capped volumes.

    Implications and outlook for research administrators

    Three practical steps follow from the current landscape. Research offices should map which grants, clusters, and cloud contracts touch controlled-threshold hardware — not just which projects have publication restrictions, since the FRE does not cover the physical item. Export-control and international-office teams should coordinate deemed-export screening for any foreign national granted administrator or remote access to a covered cluster, ahead of, not after, onboarding. And procurement teams should build multi-quarter contingency planning into capital requests, given that thresholds, tariffs, and country-tier rules have each changed at least twice since late 2024.

    Coordinating across research administration, export-control compliance, and IT procurement functions — rather than treating this as a single office’s problem — is the structural response institutions are converging on. For programmes that document international contributor roles and co-authorship arrangements, this regulatory volatility is now a standing input into partnership risk assessment, not a one-off legal review.

    The direction of travel for 2026 remains policy volatility rather than settled rules. With the Chip Security Act still pending, no Wassenaar consensus in sight, and the EU AI Act’s compute thresholds only recently operative, institutions with substantial research administration functions should expect this to remain a live compliance area rather than a rule set they can finalise once and file away.

  • AI Growth Lab: What the UK’s Regulatory Sandbox Means for University-Led AI Research

    The AI Growth Lab is the UK government’s proposal for a cross-economy regulatory sandbox that lets firms and, potentially, universities trial AI-enabled products under supervised, time-limited exemptions from rules that would otherwise block deployment. The Department for Science, Innovation and Technology (DSIT) ran a call for evidence on the proposal from 21 October 2025 to 7 January 2026, and an advisory version of the Lab launched on 8 June 2026 with legal services as the first live sector. For research offices, the question is no longer whether the Lab will exist, but how sandbox pilots intersect with university spinouts, clinical AI trials, and research infrastructure such as the AI Research Resource.

    What Is the UK AI Growth Lab?

    DSIT describes the AI Growth Lab as a “pioneering cross-economy sandbox” that would oversee controlled deployment of AI-enabled products and services in live market environments, granting participating firms time-limited regulatory exemptions known as sandbox pilots. The rationale is economic: DSIT’s call-for-evidence document cites OECD modelling suggesting AI could add 0.4 to 1.3 percentage points to UK productivity growth over the next decade — equivalent to £55 billion to £140 billion in additional annual output by 2030 — while only 21% of UK businesses currently use AI, and 60% of respondents to an earlier call for evidence identified regulation as a barrier to adoption.

    The Lab builds on precedent. The UK pioneered the modern regulatory sandbox model with the Financial Conduct Authority’s 2016 fintech sandbox, since echoed by the EU, US, Japan, Estonia and Singapore. DSIT’s proposal also references the FCA’s Innovate Project, the Bank of England/FCA Digital Securities Sandbox, the ICO’s Data Protection Sandbox, and the MHRA’s AI Airlock — the last of which is already piloting oversight of ambient voice technologies (AI tools that transcribe clinician-patient conversations) through its “TORTUS” case study.

    An advisory version of the AI Growth Lab launched on 8 June 2026, bringing together the Legal Services Board, the Solicitors Regulation Authority and other regulators to trial AI products in legal services first, with the Information Commissioner’s Office issuing a supporting statement the same day. Statutory sandbox pilots, which would require primary legislation to grant regulators modification powers, remain subject to further parliamentary process; the House of Lords debated the proposal on 26 March 2026.

    How AI Growth Lab Sandbox Pilots Work

    DSIT’s proposal sets out a consistent operating logic for sandbox pilots, regardless of sector:

    • Issue-specific sandboxes target sectors with clear AI opportunity but where existing regulation impedes adoption — legal services, planning, diagnostic imaging and micromobility/robotics are the named early candidates.
    • Time-limited exemptions are granted to eligible firms and products, allowing them to operate under modified rules while under close supervision, with the Lab able to end a pilot at any time.
    • “Red lines” stay fixed. DSIT proposes that consumer protections, safety provisions, fundamental rights, workers’ protections and intellectual property rights can never be modified or disapplied during a pilot.
    • Successful pilots feed reform. Evidence from a pilot can inform permanent regulatory change — updated guidance, codes of practice, or secondary legislation — subject to parliamentary scrutiny.

    DSIT is weighing two operating models: a centrally operated Lab run by government with an Oversight Committee of sectoral regulators, better suited to cross-sector AI applications; and regulator-operated Labs, where a lead regulator runs the sandbox for its own sector — closer to the MHRA AI Airlock precedent. The table below situates the proposed Lab against sandboxes already operating in the UK.

    Sandbox Lead body Sector focus Modification power
    FCA Innovate Sandbox Financial Conduct Authority Fintech / financial services Advisory + authorisation support
    MHRA AI Airlock Medicines and Healthcare products Regulatory Agency AI as a medical device Advisory, phased case studies
    ICO Data Protection Sandbox Information Commissioner’s Office Cross-sector data protection Advisory
    AI Growth Lab (proposed) DSIT, with sectoral regulators Cross-economy, sector pilots Statutory exemptions (“sandbox pilots”), subject to red lines

    What It Means for University-Led AI Research

    DSIT’s call-for-evidence explicitly invited responses from “a research organisation, university or think tank” as a distinct respondent category, and the proposal’s own framing links the Lab to place-based AI Growth Zones, which are designed to pair university and industry AI capacity — with embodied and infrastructure-heavy AI applications potentially gaining access to the government’s AI Research Resource (AIRR), the shared compute allocation for UK AI research. That link between a regulatory sandbox and a compute-access programme is largely absent from law-firm commentary on the Lab, which has focused on commercial and professional-services angles.

    In practice, the clearest route into a pilot for most universities runs through spinouts and licensed technology transfer, since DSIT’s proposed eligibility criteria favour applicants with a near-market product, a UK nexus, and a demonstrable regulatory barrier — not early-stage research.

    • Opportunities: real-world testing routes for spinouts translating lab research into deployable tools; potential access to data and infrastructure otherwise gated by regulation; earlier sight of which regulatory barriers government is prepared to modify.
    • Risks: eligibility criteria oriented to market-ready products rather than exploratory research; unresolved questions on intellectual property and publication timing inside a supervised pilot; added administrative and ethical-review burden for institutions without dedicated regulatory-affairs capacity.

    Research offices supporting clinical AI should note that DSIT names the Ionising Radiation (Medical Exposure) Regulations as a candidate for pilot modification, given AI’s growing accuracy in interpreting scans — a live example of a pilot touching clinical research governance directly, not just commercial deployment.

    Common Questions About the AI Growth Lab

    What is an AI Growth Lab “sandbox pilot”?

    A sandbox pilot is a time-limited, closely supervised arrangement in which an eligible firm or product receives a targeted exemption from specific regulatory requirements. DSIT can end a pilot at any time, and protections such as consumer rights and safety provisions remain fixed “red lines” throughout.

    Which sector was first to join the AI Growth Lab?

    Legal services became the first sector inside the advisory AI Growth Lab, launched on 8 June 2026 with the Legal Services Board and Solicitors Regulation Authority as founding regulators. DSIT has signalled healthcare, planning and robotics as likely next candidates for issue-specific sandboxes.

    Who can apply to participate in the AI Growth Lab?

    DSIT’s proposal envisages applications from start-ups, established companies, global AI developers and public-sector innovators, with eligibility weighted toward a UK nexus, consumer benefit, and a demonstrable regulatory barrier. Final eligibility criteria were still under consultation as of the call-for-evidence close in January 2026.

    How does the AI Growth Lab differ from AI Growth Zones?

    AI Growth Zones are place-based clusters pairing infrastructure, compute and industry investment in specific UK locations, while the AI Growth Lab is a regulatory mechanism that can operate across the whole economy. DSIT’s proposal treats the two as complementary, with place-based sandbox pilots able to draw on AI Growth Zone infrastructure.

    What Research Offices Should Track Next

    The call for evidence has closed, but several decision points remain open and directly relevant to research administration teams supporting AI-related grants, spinouts and clinical trials:

    • Eligibility criteria finalisation — whether DSIT’s final rules for the Lab explicitly recognise university research organisations or spinouts as a distinct applicant category, beyond commercial firms.
    • Sector rollout order — after legal services, which sector opens next; healthcare/diagnostic imaging and planning are the most research-relevant candidates named in the proposal.
    • Oversight model — whether DSIT adopts a centrally operated Lab or regulator-operated Labs, which will determine which single point of contact a university would need to approach.
    • Primary legislation — statutory modification powers require parliamentary approval; institutions should track Hansard and DSIT announcements for the bill’s progress following the 26 March 2026 Lords debate.
    • AI Research Resource access — whether compute allocation under AIRR becomes formally linked to sandbox participation for embodied or infrastructure-heavy AI pilots.

    None of this displaces existing research governance. Institutional ethics review, data protection obligations, and research integrity processes continue to apply inside a sandbox pilot exactly as DSIT’s “red lines” intend — the Lab modifies sector regulation, not an institution’s own duty of care. Research offices that map their AI-active spinouts and clinical-AI projects against the Lab’s likely next sectors now will be better placed to respond quickly once eligibility criteria and the second wave of issue-specific sandboxes are confirmed.

  • NIH’s Ban on AI-Generated Grant Applications: What NOT-OD-25-132 Requires

    The National Institutes of Health has put research offices on notice: proposals that look like they were written by a machine, and principal investigators who submit an implausible volume of them, will now be treated as a fairness problem rather than a productivity feature. NIH AI policy grant applications is the subject of NOT-OD-25-132, “Supporting Fairness and Originality in NIH Research Applications,” issued 17 July 2025 and effective for applications with due dates on or after 25 September 2025. The notice does two distinct things at once — it restricts the use of generative AI in drafting applications, and it caps the number of applications any one principal investigator (PI) can submit per year — and research administrators need to treat them as two separate compliance obligations, not one.

    What NOT-OD-25-132 Actually Says

    NIH’s position is narrower than “no AI allowed.” The notice states that applications must reflect the original ideas and scientific contributions of the investigators, and that NIH will not accept applications that are substantially developed by AI. That is a materiality threshold, not a blanket prohibition on tools — spell-checkers, reference managers, and light editorial assistance are not the target.

    The stated concern is specific: NIH flags plagiarism, fabricated or non-existent citations, and other misleading content generated by large language models as the practical harms it is trying to prevent, not AI use in the abstract. Applications judged to fall foul of this standard can trigger a research misconduct review and enforcement action, including referral to the Office of Research Integrity, disallowance of costs, or termination of an award already made.

    NIH published the policy as a companion pair: the formal Guide notice (NOT-OD-25-132) and an accompanying Extramural Nexus explainer, “Apply Responsibly,” released two weeks later on 31 July 2025. A supporting FAQ page clarifies edge cases such as how applications are counted and which activity codes are exempt.

    The Six-Application PI Limit, Explained

    The second, less-discussed half of the notice caps submissions. An individual PI or Program Director — including each PI listed on a Multiple PI application — may submit a maximum of six new, renewal, resubmission, or revision applications within a defined NIH Council Round. NIH has said the cap was prompted by evidence that a small number of investigators, aided by AI drafting tools, were submitting dozens of applications in a single round, in some cases reportedly more than 40, straining the peer-review system disproportionately relative to the scientific contribution.

    Council Round Applications counted toward the cap
    2026 Council Round Due dates 25 September 2025 through 7 May 2026
    2027 Council Round Due dates 25 May 2026 through 7 May 2027

    Two activity types are explicitly carved out: T-series training grants and R13 conference grants. The limit applies only to the PI/PD role — an investigator can still appear as a co-investigator, senior/key personnel, or a PI on a subaward across as many applications as the science supports, without those roles counting against their own six-application ceiling.

    • Counts toward the cap: new, renewal, resubmission, and revision applications where the individual is listed as PD/PI or Multiple PI.
    • Does not count toward the cap: T-activity-code training grants, R13 conference grants, and any application where the individual’s role is co-investigator or subaward PI rather than the lead PD/PI.
    • Counting trigger: institutional guidance (e.g., UCSF’s Office of Sponsored Research) indicates an application is counted toward the limit once it passes administrative review, prior to peer review — so late withdrawals after that point may still occupy a slot.

    PIs are responsible for tracking their own running total through eRA Commons; NIH does not promise to intercept a seventh application before submission, and rejection at that stage disrupts a funding cycle an institution cannot easily recover.

    AI Detection and Post-Award Consequences

    The most consequential detail for research offices is timing: NIH’s review for AI-substantiality is not confined to the submission window. The notice makes clear that detection can occur at the post-award stage — after funds have already been drawn down — and that a finding of substantial AI authorship at that point is treated with the same seriousness as post-hoc discovery of plagiarism or fabricated data.

    That reframes the risk calculus for institutions. A proposal that clears peer review and receives an award is not retroactively safe; institutional research integrity offices should treat AI-authorship disclosures and certifications as live documents that could be tested years into a project period, not a one-time submission checkbox.

    Compliance FAQs for Research Offices

    What is NOT-OD-25-132?

    NOT-OD-25-132 is an NIH Guide notice, “Supporting Fairness and Originality in NIH Research Applications,” issued 17 July 2025. It bars grant applications substantially developed by AI and, separately, caps most PIs at six NIH applications per year, effective for due dates from 25 September 2025.

    How many grants can one PI submit to NIH per year?

    A maximum of six new, renewal, resubmission, or revision applications per PD/PI or Multiple PI, counted per NIH Council Round rather than the calendar year strictly. T-series training grants and R13 conference grants are exempt from the count entirely.

    Does NIH ban all use of AI in grant writing?

    No. NIH restricts applications “substantially developed by AI” — content that is not the applicant’s original scientific thinking — rather than incidental editing or drafting assistance. The concern is plagiarism, fabricated citations, and misleading content, not tool use itself.

    What happens if AI use is detected after an award is made?

    NIH can pursue a research misconduct review, refer the case to the Office of Research Integrity, and take enforcement action including disallowance of costs or termination of the award — even after funding has already begun.

    Compliance Steps Before the Next Submission Cycle

    Research offices working toward the 2027 Council Round have a defined window to close process gaps. Practical steps that institutional sponsored-programs and research-integrity functions are adopting:

    • Add an explicit AI-originality certification to internal routing and sign-off forms, distinct from the existing research-misconduct and conflict-of-interest attestations.
    • Track each PI’s running six-application count centrally rather than relying on individual faculty to self-monitor eRA Commons, particularly across multi-department or multi-PI proposals.
    • Flag applications naming the same PI as PD/PI on more than six efforts early in the planning cycle, and confirm which, if any, qualify for the T-code or R13 exemption before assuming a conflict exists.
    • Brief investigators that post-award AI-authorship findings carry the same institutional exposure as post-award data-integrity findings — this is not solely a pre-submission compliance question.
    • Coordinate with departmental research administrators (the audience ARMA, NCURA, and EARMA serve) so that the cap is applied consistently across schools and centres within one institution, since NIH counts at the individual-PI level regardless of departmental structure.

    Implications for the Wider Research Ecosystem

    NOT-OD-25-132 sits inside a broader pattern: funders are converging on the idea that AI-assisted productivity gains in proposal writing are not neutral if they change who gets reviewed and how thoroughly. The six-application cap is, functionally, a peer-review capacity-protection measure as much as an integrity measure — NIH is acknowledging that AI tools changed submission economics faster than its review infrastructure could absorb.

    For research administration more broadly, the notice is also a signal that funder-side AI governance is arriving as binding operational policy, not aspirational guidance, and that institutions without a documented AI-in-proposals policy of their own are now exposed to funder-level enforcement they cannot pre-empt internally. Institutions that build durable certification and tracking workflows now — rather than treating this as a one-off notice to file away — will be better positioned as other US and international funders publish comparable AI-authorship and submission-volume rules over the next funding cycles.